Hofseth BioCare ASA (HBC) Fair Value & Analysis
Consumer Defensive · NO · Market cap 504M NOK
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price +9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.01 – kr 1.88 · fair‑value band kr 1.70 – kr 2.84 · the kr 1.25 price screens below the kr 2.27 fair value. As of Jun 23, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Hofseth BioCare ASA (HBC) currently trades at kr 1.25, while our model-based Fair Value estimate is kr 2.27 — implying the stock looks roughly 82.3% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Hofseth BioCare ASA generated revenue of 256M NOK at a net margin of -52.6%. Revenue grew 11.2% year over year. Net debt stands at 191M NOK. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hofseth BioCare ASA reported revenue of kr 256M in FY2025 versus kr 87.6M in FY2021, a compound +30.8%/yr. Reported net income was −kr 135M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $97.58 | $65.41 | -33% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥35.10 | ¥25.34 | -28% |
| Nestlé India Limited NESTLEIND | ₹1,438 | ₹362.37 | -75% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 72.19 MXN | +26% |
| Uni-President Enterprises Corp 1216 | 75.10 TWD | 72.54 TWD | -3% |
| Britannia Industries Limited BRITANNIA | ₹5,218 | ₹3,567 | -32% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Hofseth BioCare ASA (HBC) undervalued?
What is the fair value of HBC?
What is the quality score of HBC?
What is the revenue of Hofseth BioCare ASA (HBC)?
What is the net profit margin of HBC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.